Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 199-200

  Sorich, Michael J ^a   Polasek, Thomas M ^b   Wiese, Michael D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PLACEBO;

BLEEDING; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LETTER; LOSS OF FUNCTION MUTATION; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK; SYSTEMATIC REVIEW (TOPIC);

ALLELES; ARYL HYDROCARBON HYDROXYLASES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMORRHAGE; HUMANS; POLYMORPHISM, GENETIC; RISK; THROMBOSIS; TICLOPIDINE;

EID: 84863714906     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-02-0095     Document Type: Letter

References (15)

1. Bowry ADK, et al. Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. Am J Cardiol 2008; 101: 960-966.
2. Scott SA, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90: 328-332.
3. Lu CY, et al. The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: A case study of prasugrel. Clin Pharmacol Ther 2011; 90: 27-29.
4. Sorich MJ, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8: 1678-1684.
5. Polasek TM, et al. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Therapeutic Advances in Drug Safety 2011; 2: 253-261.
6. Review Manager (RevMan). Version 5.1. 5.1 ed. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen; 2011.
7. Bhatt DL, et al. Charisma Genomics Substudy: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention. Available at: http://www.clinicaltrialresults.org/Slides/CHARISMA%20Genomics.ppt. Accessed January 24, 2012.
8. Wallentin L, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
9. Mega JL, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
10. Pare G, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
11. Campo G, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
12. Sibbing D, et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation 2010; 121: 512-518.
13. Luo Y, et al. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res 2011; 39: 2012-2019.
14. Harmsze AM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175.
15. Zabalza M, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-offunction polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-108